Literature DB >> 7485142

Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity.

M Wang1, G Hercz, D J Sherrard, N A Maloney, G V Segre, Y Pei.   

Abstract

With the markedly reduced usage of aluminum salts in renal failure, parathyroid hormone (PTH) has become the major determinant of currently seen bone disease. Clinicians now must consider what PTH level should be sought. Too low a level may lead to the aplastic bone lesion (low turnover bone), and too high a level may cause osteitis fibrosa. Furthermore, conventional normal PTH levels may not be a suitable target because of the well-known resistance to PTH in uremic patients. In this report, we derive the PTH levels that best distinguish patients with low and high bone formation states from those with normal bone formation in a group of 175 dialysis patients without aluminum toxicity. Using bone histological parameters, we propose that ideally PTH levels should be maintained between 10 pmol/L (100 pg/mL) and 20 to 30 pmol/L (200 to 300 pg/mL) in chronic dialysis patients, levels two to four times the upper limit of values found in normal subjects.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7485142     DOI: 10.1016/0272-6386(95)90453-0

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  36 in total

Review 1.  Renal osteodystrophy.

Authors:  E A González; K J Martin
Journal:  Rev Endocr Metab Disord       Date:  2001-04       Impact factor: 6.514

Review 2.  Diseases of the parathyroid gland in chronic kidney disease.

Authors:  Hirotaka Komaba; Takatoshi Kakuta; Masafumi Fukagawa
Journal:  Clin Exp Nephrol       Date:  2011-08-06       Impact factor: 2.801

3.  Bone mineral density and parathyroid function in patients on maintenance hemodialysis.

Authors:  Cs Ambrus; Cs Almasi; K Berta; Gy Deak; A Marton; M Zs Molnar; Zs Nemeth; Cs Horvath; P Lakatos; M Szathmari; I Mucsi
Journal:  Int Urol Nephrol       Date:  2010-01-21       Impact factor: 2.370

4.  Intact PTH combined with the PTH ratio for diagnosis of bone turnover in dialysis patients: a diagnostic test study.

Authors:  Johann Herberth; Adam J Branscum; Hanna Mawad; Tom Cantor; Marie-Claude Monier-Faugere; Hartmut H Malluche
Journal:  Am J Kidney Dis       Date:  2010-03-27       Impact factor: 8.860

5.  Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients.

Authors:  Hartmut H Malluche; Hanna W Mawad; Marie-Claude Monier-Faugere
Journal:  J Bone Miner Res       Date:  2011-06       Impact factor: 6.741

6.  Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease.

Authors:  Jason R Stubbs; Nan He; Arun Idiculla; Ryan Gillihan; Shiguang Liu; Valentin David; Yan Hong; L Darryl Quarles
Journal:  J Bone Miner Res       Date:  2012-01       Impact factor: 6.741

7.  Prolonged hospital stay after parathyroidectomy for secondary hyperparathyroidism.

Authors:  Shih-Ping Cheng; Chien-Liang Liu; Han-Hsiang Chen; Jie-Jen Lee; Tsang-Pai Liu; Tsen-Long Yang
Journal:  World J Surg       Date:  2009-01       Impact factor: 3.352

Review 8.  Bone and mineral disorders after kidney transplantation: therapeutic strategies.

Authors:  Miklos Z Molnar; Mohamed S Naser; Connie M Rhee; Kamyar Kalantar-Zadeh; Suphamai Bunnapradist
Journal:  Transplant Rev (Orlando)       Date:  2013-12-12       Impact factor: 3.943

Review 9.  The role of bone biopsy in patients with chronic renal failure.

Authors:  Paul D Miller
Journal:  Clin J Am Soc Nephrol       Date:  2008-11       Impact factor: 8.237

10.  Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis.

Authors:  Katherine Wesseling-Perry; Renata C Pereira; Hejing Wang; Robert M Elashoff; Shobha Sahney; Barbara Gales; Harald Jüppner; Isidro B Salusky
Journal:  J Clin Endocrinol Metab       Date:  2008-12-02       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.